Safety
upper respiratory tract infections, femur fracture, constipation
ADVERSE EVENTS, UPPER RESPIRATORY TRACT INFECTIONS
No safety concerns emerged during the study. One serious AE was reported in a patient receiving erenumab (femur fracture), and treatment emergent AEs were essentially limited to constipation (10%) and upper respiratory tract infections (7%). Treatment emergent adverse events are described in Supplementary Table 13. No significant changes in laboratory parameters or physical findings were observed.